Conference Coverage

VIDEO: Researchers closing in on the elusive ‘male pill’


 

REPORTING FROM ENDO 2018

Some men reported a drop in libido that resolved by the end of the study. There was also mild weight gain and small reductions in HDL cholesterol. A few tweaks to the formulation or dosing might fix those problems. “Overall, we were very encouraged about the safety profile,” Dr. Page said.

Robert Lodge

Dr. Stephanie Page Stills

She explained the work, its promise, and the next steps in a video interview at the Endocrine Society’s annual meeting. The National Institutes of Health is funding development. Dr. Page didn’t have any relevant disclosures.

SOURCE: Page S et al. ENDO 2018, Abstract OR15-2.

Pages

Recommended Reading

Testosterone: Moderate sexual, mood benefits; no vitality benefit
MDedge Cardiology
Drug interaction myths
MDedge Cardiology
VIDEO: Telecardiology improves chronic care management, reduces cost
MDedge Cardiology
AAA screening showed no mortality reduction in new trial
MDedge Cardiology
New PAD guidelines expected to boost awareness and treatment
MDedge Cardiology
The Barbershop Study: Hypertension causes nocturia
MDedge Cardiology
Clinicians underusing statins, aspirin in HIV patients
MDedge Cardiology
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Cardiology
Alpha-blockers deemed safe in heart failure
MDedge Cardiology
Nocturia linked to hypertension, diuretic use in community-based study of black men
MDedge Cardiology